Despite the rising incidence of Central Nervous System diseases worldwide, efficient treatment options for neurological disorders remain scarce. Treatment failures are principally associated with the inability of drugs to pass the highly selective Blood-Brain Barrier rather than a lack of efficacy.
Dr Nazneen Rahman, Founder and CEO of YewMaker and Sustainable Medicines Partnership (SMP) Director, describes why tackling wasted medicines is key to delivering a Net Zero NHS.
Cannabis legislation is threatening to reduce pharmaceutical stock value by billions of dollars as more people are predicted to opt for weed over opioids.
Medical cannabis remains difficult to attain in healthcare under the British government, but it holds great promise for both NHS patients and the economy.
